Silver Book Fact

It has been estimated that monthly use of ranibizumab in individuals with age-related macular degeneration (AMD) would reduce the incidence of legal blindness by 72% and visual impairment by 37%, in 2 years.  This means that 11,784 people would be spared blindness in that time period.

Bressler N, Doan Q, Varma R, Lee P, et al. Estimated Cases of Legal Blindness and Visual Impairment Avoided Using Ranibizumab for Choroidal Neovascularization: Non-Hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol. 2011; 129(6): 709-717. http://jamanetwork.com/journals/jamaophthalmology/fullarticle/427350

Reference

Title
Estimated Cases of Legal Blindness and Visual Impairment Avoided Using Ranibizumab for Choroidal Neovascularization: Non-Hispanic white population in the United States with age-related macular degeneration
Publication
Arch Ophthalmol
Publication Date
2011
Authors
Bressler N, Doan Q, Varma R, Lee P, et al
Volume & Issue
Volume 129, Issue 6
Pages
709-717
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • AMD risk reduction through diet
    A recent study indicated that 20% of AMD cases in the AREDS study would have been eliminated if the participants consumed diets with a dGI (dietary glycemic index) below the…  
  • Treatments that have been found to delay or prevent diabetic retinopathy save the U.S. $1.6 billion annually.  
  • Laser Treatment for DR
    Laser treatment of PDR can reduce the 5-year risk of blindness by 90%, and the risk of visual loss from DME by 50%.  
  • It has been estimated that monthly use of ranibizumab in individuals with age-related macular degeneration (AMD) would reduce the incidence of legal blindness by 72% and visual impairment by 37%,…  
  • Anti-VEGF Visual Improvement
    Nearly 50% of DME patients who received an anti-VEGF drug, experienced substantial visual improvement after a year of injections.